Search
Displaying 401–410 of 866 results for “vision connection”
-
Disease
Mutations in PRPH2 are a relatively common cause of several inherited retinal degenerations, including: retinitis pigmentosa (RP), pattern macular dystrophies (PMDs), cone-rod dystrophies (CRDs), and central areolar choroidal dystrophy (CACD).
-
Progress toward a stem cell–based therapy for blindness
In the PressA multi-institutional effort led by researchers at the School of Veterinary Medicine is taking steps to develop an effective technique to regenerate photoreceptors cells and restore sight in people with vision disorders.
-
Research News
The emerging therapy is designed to restore vision for people with advanced retinal degenerative diseases
-
Apellis’ Treatment for Advanced Dry AMD to Receive Priority Review from FDA
Research NewsThere are currently no FDA-approved therapies for geographic atrophy (GA), the advanced form of dry AMD.
-
Luxa Doses First Participant in Clinical Trial of RPE Stem Cells for Dry AMD Patients
Research NewsThe company’s RPESC-RPE cell product is composed of progenitor-stage RPE cells grown from human eyes donated to eye banks.
-
Enhanced Implantable Miniature Telescope Moving into Clinical Trial for AMD Patients
Research NewsThe device is designed for people with late-stage AMD who have no treatment options
-
Encouraging Clinical Trial Results for Alkeus’ Stargardt Disease Treatment
Research NewsThe company is also conducting a Phase 3 clinical trial of the emerging therapy for geographic atrophy.
-
The Karen And Basil Petrou Legacy Education Initiative
The Basil and Karen Petrou Education Initiative is born of the Foundation’s commitment to helping individuals ensure their estates do the best they can for their loved ones and the causes they care about. Debuting this year, the program will offer ongoing resources to help individuals and families explore and learn about end-of-life plans and strategies.
-
Kriya Therapeutics Licenses Emerging Foundation-Funded Dry AMD Gene Therapy
Research NewsThe Foundation Fighting Blindness is funding Bärb Rohrer, PhD, Medical University of South Carolina, to evaluate safety and efficacy of the gene therapy in a large animal model
-
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
Research NewsThe clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
.png)
.png)
